Would you use low-dose infliximab as adjunctive therapy in a patient with severe central nervous system tuberculosis?

I would not routinely use low-dose infliximab as adjunctive therapy in patients with severe central nervous system tuberculosis at this time.

The biological rationale is understandable. Tumor necrosis factor–α plays a central role in the inflammatory cascade that drives tissue damage in tuberculous ...